Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase – Here’s What Happened

Bavarian Nordic (OTCMKTS:BVNRY) shares saw an uptick in trading volume on Thursday. 18,499 shares were traded during trading, an increase of 475% from the previous session’s volume of 3,216 shares. The stock last traded at $10.81 and had previously closed at $11.1095.

Bavarian Nordic Stock Performance

The stock has a market cap of $2.57 billion, a price-to-earnings ratio of 10.92 and a beta of 1.20. The company’s 50 day simple moving average is $10.22 and its two-hundred day simple moving average is $9.86.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings results on Friday, August 21st. The company reported $0.46 EPS for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%. The business had revenue of $316.47 million for the quarter.

About Bavarian Nordic

Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.

Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.